Joshua Ofman Sells 2,937 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 2,937 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $47.89, for a total transaction of $140,652.93. Following the completion of the transaction, the president directly owned 432,881 shares in the company, valued at $20,730,671.09. This trade represents a 0.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $48.67 on Wednesday. The firm has a fifty day moving average price of $87.41 and a 200 day moving average price of $78.10. GRAIL, Inc. has a fifty-two week low of $20.44 and a fifty-two week high of $118.84. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -4.35 and a beta of 5.18.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. The company had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. As a group, research analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Morgan Stanley reduced their target price on GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Guggenheim lifted their price objective on GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Robert W. Baird set a $82.00 price objective on GRAIL in a report on Friday, February 20th. Finally, TD Cowen started coverage on GRAIL in a research report on Thursday, February 19th. They set a “hold” rating and a $114.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $90.17.

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Institutions adding stakes: Several large funds materially increased positions in Q4 (Farallon, Morgan Stanley, State Street, Baker Bros.), signaling confidence from sophisticated investors and providing a steady demand base. MarketBeat institutional ownership summary
• Positive Sentiment: Recent quarterly results beat EPS estimates (reported ($2.44) vs consensus ($3.33)) and revenue was roughly in line, which supports the case that core business traction (Galleri test adoption) is progressing. (Market reaction is mixed given continued multi-year losses.) Earnings & analyst summary
• Neutral Sentiment: Mixed analyst activity: Some firms trimmed price targets (Morgan Stanley cut to $60, Canaccord lowered targets), while others remain bullish (Guggenheim raised its target earlier). Overall consensus remains around a “Hold” with divergent price targets, adding to uncertainty on near-term direction. Analyst notes
• Negative Sentiment: Short interest jumped in February to ~6.3M shares (16.2% of float), up ~15% from mid‑February; days-to-cover ~1.9. A higher short percent increases downward pressure and volatility, especially given GRAL’s high beta. (Elevated shorting can amplify declines while also enabling short‑squeeze risk.)
• Negative Sentiment: Insider selling by top executives: CEO Robert Ragusa, President Joshua Ofman and CFO Aaron Freidin reported multiple sales in early March (CEO sale filings: Read More.; President filings: Read More.; CFO filings: Read More.). While sizes are modest vs. their holdings, clustered executive sales can spook investors and weigh on sentiment. InsiderTrades article

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GRAL. N.E.W. Advisory Services LLC purchased a new position in GRAIL in the fourth quarter worth about $26,000. Comerica Bank raised its position in GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in GRAIL during the fourth quarter valued at approximately $28,000. Elyxium Wealth LLC bought a new stake in shares of GRAIL in the 4th quarter valued at approximately $31,000. Finally, Intesa Sanpaolo S.p.A. purchased a new position in shares of GRAIL in the 4th quarter worth approximately $44,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.